Diagnosis and Management of Aspergillosis
Publication Date: July 25, 2016
Last Updated: December 16, 2022
Epidemiology and Risk Factors
Hospitalized allogeneic HSCT recipients should be placed in a protected environment to reduce mold exposure. ( S , L)
705
Prophylaxis
The IDSA recommends prophylaxis with posaconazole, ( S , H)
705
voriconazole, ( S , M)
705
during prolonged neutropenia for those who are at high risk for IA. ( S , H)
705
Prophylaxis with caspofungin is also probably effective. ( W , L)
705
Prophylaxis with itraconazole is effective, but therapy may be limited by absorption and tolerability. ( S , M)
705
Triazoles should not be co-administered with other agents known to have potentially toxic levels with concurrent triazole co-administration (such as vinca alkaloids, and others). ( S , M)
705
Title
Diagnosis and Management of Aspergillosis
Authoring Organization
Infectious Diseases Society of America